An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
Phase of Trial: Phase III
Latest Information Update: 21 Jul 2018
At a glance
- Drugs Evinacumab (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Adverse reactions; Registrational
- Sponsors Regeneron Pharmaceuticals
- 02 May 2018 Planned End Date changed from 6 Oct 2022 to 1 Apr 2022.
- 02 May 2018 Planned primary completion date changed from 6 Oct 2022 to 1 Apr 2022.
- 17 Jan 2018 Status changed from planning to recruiting.